A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...

XOMA Royalty’s acquisition of Turnstone Biologics highlights how royalty deals can revive biopharma companies and drive ...

The mood is better than the numbers suggest. The doom-loop panic of March and April is behind us, even though the XBI has ...

Trump’s tax bill could reshape drug R&D, manufacturing, Medicaid access, clinical trials, and biotech funding, impacting ...

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ...

Every year, horseshoe crabs are harvested for their blue blood, but alternatives are now coming through that could help ...

Canadian exports less than 5% of all generic medicines sold in the U.S., but Canada 'could get caught in the crossfire if ...

Biopharma got perilously close to having demand for uniquely skilled and experienced workers outstrip supply during the COVID ...

The strategies that the industry’s lobbyists use, or don’t deploy, matter as the Trump administration moves more decisively ...

China's biotech sector is rapidly advancing due to heavy R&D investment and a push for technological self-sufficiency. See ...

Ocugen co-founder and CEO Shankar Musunuri, Ph.D. explains what biotech leaders can learn from the Philadelphia Eagles, an agile team with a championship mindset.